Search results for: Multi-Indication Therapies
Filter search results
Payment Models for Multi-Indication Therapies
1 November 2021
…Cookson, G., 2021. Expert Consensus Programme: Payment Models for Multi-Indication Therapies. OHE Consulting Report, London: Office of Health Economics. Available at: https://www.ohe.org/publications/payment-models-multi-indication-therapies See here for the report appendices. Related Research…
Collaborating on Payment Models to Unlock the Potential of Multi-Indication Therapies.
22 June 2022, 2:00pm
…as monotherapy or in combination with other therapies as part of treatment regimens. For the growing number of these multi-indication medicines access may be delayed or even denied due to…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…be inconsistent and distortionary for it to influence the multi-indication medicine policy context. This would put patient populations for whom treatment advances arise more commonly from multi-indication products – such…
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
…Payment Models for Multi-Indication Therapies. Office of Health Economics; 2021. Accessed December 14, 2021. https://www.ohe.org/publications/payment-models-multi-indication-therapies Henderson N, Firth I, Errea M, Skedgel C, Jofre-Bonet M. A Case Study Analysis: Challenges…
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
…adherence in all cases and the prolonged treatment effect of LA therapies may extend or lead to different side effects compared to short-acting therapies. Quality of life (QoL): LA therapies…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
…OHE Briefing on the topic of multi-indication pricing. The briefing contains a summary of a workshop organised and facilitated by OHE and MME Europe. Multi-indication pricing (MIP) involves setting a…
Approaches, Challenges and Successful Stories of Multi-indication Pricing in Europe
28 November 2018
Multi-Indication Pricing: Practical Solutions and Steps to Move Forward. A summary of an HTAi panel session. We have just published a new OHE Briefing entitled ‘Multi-Indication Pricing: Practical Solutions and…
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
…discounting to gene therapies could delay or prevent patients from accessing potentially transformative therapies. The discounting challenge is not unique to gene therapies. Other health technologies like cell therapies, vaccines,…
Indication-Based Pricing: Are We All Onboard?
12 May 2020
…https://www.ohe.org/publications/multi-indication-pricing-mip-practical-solutions-and-steps-move-forward# Mestre-Ferrandiz,J., Towse, A., Dellamano, R., and Pistollato, M. (2015). Multi-indication Pricing: Pros, Cons and Applicability to the UK. Seminar Briefing 56. Office of Health Economics. Available at: https://www.ohe.org/publications/multi-indication-pricing-pros-cons-and-applicability-uk …